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Epidermal growth factor receptor is overexpressed and/or ampliﬁed in up to 50% of glioblastomas, suggesting an important
role of this gene in glial tumorigenesis and progression. In the present study we demonstrated that epidermal growth factor
receptor is involved in regulation of telomerase activity in glioblastoma. Antisense-epidermal growth factor receptor approach
was used to inhibit epidermal growth factor receptor expression of glioblastoma U87MG cells. Telomerase activity in
antisense-epidermal growth factor receptor cells decreased by up to 54 folds compared with control cells. Moreover, the
telomere lengths of antisense-epidermal growth factor receptor cells were shortened. In addition, the tumorigenicity of
antisense-epidermal growth factor receptor cells was signiﬁcantly inhibited. Taken together, there were strong correlations
between tumorigenicity and epidermal growth factor receptor expression levels, and between tumorigenicity and telomerase
activity. These results provide evidence that epidermal growth factor receptor plays an important role in the regulation of
telomerase activity of glioma cells. Our ﬁndings provide new insights into both the biological functions of epidermal growth
factor receptor and the regulation of telomerase activity. The inhibition of telomerase activity triggered by antisense-epidermal
growth factor receptor treatment may reﬂect yet another mechanism of antisense-epidermal growth factor receptor approach
in tumour suppression.
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The epidermal growth factor receptor (EGFR) is a transmembrane
glycoprotein of 170 kDa and is composed of an extracellular
ligand-binding domain, a single hydrophobic membrane-spanning
domain and a cytoplasmic tyrosine kinase domain (Yamada et al,
1997). In the EGFR-Ras signalling pathway, the binding of ligands
to EGFR activates Ras, which then activates Raf. The activated Raf
kinase can initiate the mitogen activated protein (MAP) kinase
cascade. The activated MAP kinase then migrates into the nucleus
and there phosphorylates many transcription factors such as c-myc,
c-jun, and c-ets, which affect gene expression and ultimately cell
growth (Yamada et al, 1997; Tang et al, 1997).
In addition to serving a normal physiological function, aberrant
expression of EGFR has also been linked with a number of pre-
malignant or malignant diseases, including benign hyperplasia of
the skin, mammary carcinoma, glioblastoma, and hepatic carcino-
ma (Khazaie et al, 1993). In glioblastoma, EGFR is found to be
overexpressed and /or ampliﬁed in up to 50% of all cases, suggest-
ing an important role of this gene in glial tumorigenesis and
progression (Ng and Lam, 1998). The use of antisense-EGFR
RNA to block the function of enhanced EGFR in human glioblas-
toma cells has been reported to inhibit cellular proliferation and
induce differentiation (Tian et al, 1998). Antisense-EGFR transfec-
tion in rat C6 glioma cells was also found to inhibit cellular
proliferation and induce apoptosis (Pu et al, 2000). However, the
effects of antisense-EGFR on telomerase activity and telomere
length are still unknown.
MATERIALS AND METHODS
Construction of antisense-EGFR vector
The construction of the antisense-EGFR construct and the cloning
of the transfected cells have been described previously (Tian et al,
1998). The EGFR cDNA fragment (BamHI-BamHI) derived from
PE7 was inserted in reverse orientation at the BamHI site of the
pBabe-puro vector (Morgenstern and Land, 1990). This cDNA
corresponds to the last 256 amino acid residues of the extracellular
domain, the entire transmembrane domain and the ﬁrst 61 amino
acid residues of the cytoplasmic domain of EGFR.
Cell culture and transfection
The human glioblastoma cell line U87MG (American Type
Culture Collection, Rockville, MD, USA) was grown in Minimum
Essential Medium-alpha (MEM-a) medium (Gibco, Grand Island,
NY, USA) supplemented with 10% foetal bovine serum,
100 mgm l
71 streptomycin and 100 U ml
71 penicillin, in a humi-
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www.bjcancer.comdiﬁed atmosphere of 5% CO2 at 378C. Cells were transfected with
the antisense-EGFR constructs using the Transfectam reagent
(Promega Corp., Madison, WI, USA). Clones stably expressing
undetectable or low levels of EGFR protein (AS-1, AS-3), were
selected in 1 mgm l
71 puromycin (Sigma Chemical Co., St. Louis,
MO, USA) as described previously (Tian et al, 1998). U87MG
cells were also transfected with pBabe-puro vector to serve as a
control.
Telomeric repeat ampliﬁcation protocol (TRAP) assay
TRAP-eze telomerase detection kit (Oncor) was used for telomer-
ase extraction and TRAP assay according to the manufacturer’s
protocol with minor modiﬁcations as previously described (Chong
et al, 1998). The TRAP assay was performed in a 12.5 ml reaction
mixture containing cell extract (5, 1, 0.2, or 0.04 mg), 0.05 mM
dNTP,
32P-end-labelled TS primer (5'AATCCGTCGAGCAGAG-
TT3'), primer mix (including a primer K1 and a template TSK1
for ampliﬁcation of a 36-bp internal standard) and 0.5 unit of
Taq DNA polymerase (Perkin-Elmer Cetus). After 20 min incuba-
tion at 308C in the thermocycler block to allow telomerase-
mediated extension of the TS primer, 30 cycles of PCR was
performed at 948C for 30 s, 588C for 30 s, and 728C for 30 s.
Incorporation of the PCR internal standard allows identiﬁcation
of false-negative samples that may contain Taq polymerase inhibi-
tors. The PCR products were examined by electrophoresis on a
12.5% non-denaturing polyacrylamide gel. Quantiﬁcation of
samples was performed using the InstantImager (Packard, Meri-
den, CT, USA) for electronic autoradiography. A heat-
inactivated (858C for 10 min) telomerase control, 16CHAPS lysis
buffer only control, and the TSR8 quantiﬁcation control were
included for each set of TRAP assays according to the manufac-
turer’s instruction. The TRAP assay was repeated twice for each
sample.
Measurement of terminal restriction fragment (TRF)
length by Southern blot hybridisation
Terminal restriction fragment (TRF) length, which is a measure of
telomere length, was measured by Southern blot hybridisation.
High-molecular-weight DNA was prepared from cultured cells
using the standard procedures, including proteinase K treatment
and phenol/chloroform extraction. Three micrograms of DNA
from each cell line was digested overnight with the restriction
endonuclease HaeIII (Amersham Pharmacia Biotech, Buckingham-
shire, UK). Electrophoresis through a 1% agarose gel and Southern
transfer to a nylon membrane were performed as previously
described (Counter et al, 1992). The synthetic oligonucleotide
(TTAGGG)4 was end-labelled with [g-
32P]ATP and used as a hybri-
disation probe to detect telomeric repeats. Hybridisation was
carried out at 508C for 2 h in Rapid-hyb buffer (Amersham Phar-
macia Biotech). This membrane was ﬁnally washed at 428Ci n
26SSC/0.1% SDS (16SSC: 0.15 M NaCl and 0.02 M sodium
Citrate), then autoradiographed. The densitometric peak of smear
signal was deﬁned in this study as the peak TRF length. Quantiﬁ-
cation of signals was carried out using Fluor-S MultiImager (Bio-
Rad Laboratories).
Tumorigenicity study of antisense-EGFR transfected cells
Balb/c nude mice, 6–8 weeks old, obtained from the Animal
Resources Center, Western Australia, were housed in pathogen-free
facilities. Ten mice were divided into four groups: two each for
U87MG parental cells and empty vector-transfected cells and three
each for AS-1 and AS-3 clones. Five million viable cells from each
cell line were injected subcutaneously into the ﬂank of each nude
mouse of the relevant group. Tumour diameters in 3 dimensions
were measured with linear calipers 1 week after inoculation, and
tumour volumes were calculated as their product. This experiment
was performed twice.
RESULTS
Human U87MG glioma cells successfully transfected with
antisense-EGFR
The antisense-EGFR constructs were transfected into a glioblas-
toma cell line U87MG and stable transfected clones were
isolated. The effect of antisense EGFR RNA on the expression
of EGFR protein was evaluated by Western blot analysis using
a rabbit anti-human EGFR polyclonal antibody. Parental cells
and cells transfected with empty vector (denoted as U87MG/
pBabe) expressed high level of EGFR protein. The protein level
of EGFR was reduced about ﬁve-fold in antisense-EGFR clone
AS-3, and was undetectable in antisense-EGFR clone AS-1.
These successfully transfected antisense-EGFR clones were found
to have impaired proliferation, reduced transforming potential
as well as cellular differentiation (Tian et al, 1998). In this
study, antisense-EGFR clones AS-1 (the most inhibited clone)
and AS-3 (the intermediately inhibited clone) were further
analysed in subsequent experiments. U87MG/pBabe cells were
used as a control.
Telomerase activity
Telomerase activity, depicted by the incremental 6-nucleotide
ladder, was detected in both empty vector-transfected and parental
cells (Figure 1). Pretreatment of cell extracts with heat abolished
the laddering patterns, conﬁrming the speciﬁc detection of telo-
merase activity. The cell extracts appeared to contain inhibitory
activity against PCR reaction, as revealed by the absence of internal
control TSK1 signal, when 5 mg of protein was used. The extension
of the characteristic 6-base ladder and the appearance of the TSK1
band occurred after dilution of the cell extracts. In control cells,
telomerase activity was detected from 1 to 0.04 mg (5–125-fold
diluted) protein extract (Figure 1). In antisense-EGFR clone AS-
1, the 6-base ladders were much weaker at 1 and 0.2 mg extract
than the corresponding protein concentrations in control cells,
and the activity was undetectable in 0.04 mg protein extract. A
quantitative assessment of telomerase activity was performed by
comparing the intensity of the 6-base ladders from 0.2 mg cell
extracts of AS-1 and AS-3 to that of the control (TSR8). The
experiment was performed three times. There was no signiﬁcant
difference in telomerase activity between parental cells and empty
vector-transfected cells. However, telomerase activity decreased
54-fold and 2.5-fold in AS-1 (P50.001 ) and AS-3 (P50.05),
respectively, when compared to that of the control cells. These
results showed a strong correlation of telomerase activity with
the expression levels of EGFR, indicating a role of EGFR in the
regulation of telomerase activity.
TRF length in antisense-EGFR transfected cells
Same passages of control cells and antisense-EGFR transfected cells
were used to analyse TRF length. Figure 2 shows the hybridisation
of the (TTAGGG)4 probe to HaeIII-digested DNA from control
cells and antisense-EGFR transfected cells. The densitometric peak
in smear signal was taken as the peak TRF length. The peak TRF
lengths were similar in parental U87MG cells (7.6 kb) and empty
vector-transfected cells U87MG/pBabe (7.2 kb), whereas the peak
TRF lengths were shortened in antisense-EGFR clone AS-1
(3.8 kb) and AS-3 (4.1 kb). AS-1, which expressed lowest telomer-
ase activity, had the shortest peak TRF length. This experiment was
performed twice and similar result was obtained. Thus, the peak
TRF length correlated well with the telomerase activity of
U87MG cells.
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We tested whether the expression of antisense-EGFR RNA had any
effect on the ability of glioblastoma cells to form tumours in athy-
mic nude mice. Control cells and antisense-EGFR transfected cells
were injected into nude mice subcutaneously, and tumour volumes
were measured for the duration of the experiments. At 3 weeks of
post-implantation (Table 1), examination of nude mice revealed no
signiﬁcant difference in tumour volumes between U87MG and
vector alone cells, and the control sections of the experiments were
terminated. At this time point, however, AS-3 cells formed smaller
tumours (P50.001) in nude mice than control cells, and AS-1 had
not yet produced visible tumours. Therefore, the monitoring of the
nude mice injected with antisense-EGFR transfected cells was
continued until tumour volumes reached *1000 mm
3. AS-3 cells,
expressing intermediate levels of EGFR, formed tumours of
*1000 mm
3 after 4 weeks post-implantation. Whereas, AS-1 cells,
expressing the lowest levels of EGFR, required 16–18 weeks, to
grow to a similar extent. There were strong correlations between
tumorigenicity and EGFR expression levels, and between tumori-
genicity and telomerase activity.
DISCUSSION
In this study, glioblastoma U87MG cells that were previously
shown to over-express EGFR, were transfected with the antisense-
EGFR constructs. The stable transfectants expressed low or unde-
tectable levels of EGFR protein (Tian et al, 1998). These
transfected cells were found to be weakly- or non-responsive to
epidermal growth factor induced cell growth (Tian et al, 1999).
Although the mechanism of action is not clear, the antisense
approach used in this study demonstrated high speciﬁcity toward
inhibition of endogenous EGFR expression. These transfected cells
were suppressed in cell growth in vitro, increased in G1 arrest and
decreased in Ki-67 staining (Tian et al, 1998).
Activation of telomerase, compensating for the loss of telomeres,
has been implicated in human cell immortalisation and carcinogen-
esis. Three human telomerase-associated molecules, human
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Figure 1 Telomerase activity in U87MG cells, empty vector-transfected cells (U87MG/pBabe), antisense-EGFR transfected cells AS-1 and AS-3. There
was no signiﬁcant difference in the telomerase activity between parental and empty vector-transfected cells. However, the telomerase activity reduced 54
folds and 2.5 folds in AS-1 (P50.001) and AS-3 (P50.05), respectively, when compared to that of the control cells. The negative control was lysis buffer and
the positive control was provided by the TRAP-eze telomerase detection kit. TSR8 (control template) was used as a quantiﬁcation control. TSK1 was the
internal standard of PCR.
23130 bp —
9416 bp —
6557 bp —
4361 bp —
2322 bp —
2027 bp —
U87MG
U87MG/pBabe
AS-1
AS-3
Figure 2 TRF length analysis by Southern blot of HaeIII-digested DNA
with the telomere-speciﬁc probe (TTAGGG)4. The densitometric peak in
smear signal was taken as the peak TRF length. The peak TRF lengths were
7.6, 7.2, 3.8 and 4.1 kb in parental U87MG cell, empty vector-transfected
cells (U87MG/pBabe), antisense-EGFR transfected clones AS-1 and AS-3,
respectively. The peak TRF lengths of control cells and antisense-EGFR
transfected cells correlated well with the telomerase activity.
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(hTERT) and telomerase-associated protein (hTEP1), have been
identiﬁed. Its RNA subunit acts as a template for the synthesis of
telomeric DNA, whereas hTERT catalyses this process to make
up for the inability of conventional DNA polymerase to replicate
completely the ends of linear DNA. hTEP1 is associated with telo-
merase activity and the telomerase reverse transcriptase, and it
speciﬁcally interacts with the telomerase RNA (Dhaene et al,
2000). Wu et al (1999) has demonstrated that c-myc, a down-
stream target of EGFR, can directly activate telomerase by inducing
expression of the catalytic subunit of hTERT.
There were only two studies reporting an association of EGFR
with telomerase activity. Kunimura et al (1998) dissociated
primary human epithelial cells of uterine cervix into several
distinctive cellular subsets by immunocytochemical cell fractiona-
tion. They found that telomerase activity was positive in the
subset which expressed predominantly integrin beta 1 and EGFR,
but was negative in the subset which strongly co-expressed
p75NGFR, integrin beta 4 and bcl-2. Their work showed a
phenomenon that EGFR expression and telomerase activity co-
existed in the subset. In a mouse model, Inui et al (2002) demon-
strated that after partial hepatectomy regenerating hepatocytes
showed upregulation of telomerase activity. They further showed
that preoperative treatment of EGF increased the in vivo telomer-
ase activity. Such an increase in telomerase activity was also
demonstrated in regenerating hepatocyte culture treated with
EGF. Moreover, treatment with MEK inhibitors signiﬁcantly
repressed telomerase activity. Their ﬁndings suggest that EGF
plays an important role in the activation of telomerase activity
in liver regeneration. In this study, antisense-EGFR transfected
cells expressed much lower telomerase activity than control cells
did. AS-3 cells, which expressed intermediate level of EGFR,
exhibited much higher telomerase activity than AS-1, which
expressed the lowest level of EGFR. Thus, a direct correlation
was observed between the levels of EGFR expression and telomer-
ase activity. Our results show that EGFR is associated with
regulation of telomerase activity in glioma cells, although the
mechanism is currently unclear.
Telomerase activity has been shown to be speciﬁcally expressed
in immortal cells, cancer cells and germline tissues, where it
compensates for telomere shortening during DNA replication
and thus stabilises telomere length (Dhaene et al, 2000). Our
results showed that empty vector-transfected cells had the same
peak TRF length as the parental U87MG cells, suggesting that
the high telomerase activity in control cells can stabilise telomere
length. Antisense-EGFR transfected cells, which expressed low
telomerase activity, exhibited shorter peak TRF length than
control cells, this result is in keeping with the role of telomerase
for maintenance of telomere. Murakami et al (1999) used reverse
transcriptase inhibitors, dideoxyinosine (ddI) and AZT-5' tripho-
sphate (AZT-TP), to inhibit telomerase activity of gynaecological
cancer cells. They found that ddI and AZT-TP treatment of
tumour cells reduced telomerase activity, shortened the length of
the telomere and increased p53 expression. Hahn et al (1999)
exhibited that expression of a mutant catalytic subunit of human
telomerase resulted in complete inhibition of telomerase activity,
reduction in telomere length, death of tumour cells and elimina-
tion of tumorigenicity in vivo. Our study demonstrated that
antisense-EGFR approach could also suppress telomerase activity
in glioma cells. Antisense-EGFR transfection of U87MG cells
resulted in inhibition of telomerase activity and tumorigenicity,
reduction in telomere length, increase in p53 expression (Tian
et al, 1999) and apoptosis induced by cisplatin (Tian et al, unpub-
lished data). There were strong correlations between
tumorigenicity and EGFR expression levels, and between tumori-
genicity and telomerase activity. Thus, the ﬁnding that
antisense-EGFR transfection induces a decrease in telomerase
activity and telomere length suggests a novel mechanism of anti-
sense-EGFR treatment in inhibiting cellular proliferation.
In an attempt to elucidate the mechanism of EGFR in regulat-
ing telomerase activity, we evaluated the transcriptional levels of
c-myc, hTERT and hTEP1. Semiquantitative RT-PCR assay
showed no signiﬁcant difference in the transcriptional levels of
c-myc, hTERT and hTEP1 between antisense-EGFR cells and
control cells (data not shown). Many research groups have
demonstrated that telomerase activity correlates well with hTERT
expression, but not with hTEP1 expression (Dhaene et al, 2000).
Recently, a few reports showed that hTERT expression was not
related with telomerase activity (Kameshima et al, 2001; Liu et
al, 2001). Actually, the mechanisms regulating the production of
active telomerase enzymes are still predominantly unknown,
although roles for transcriptional control of hTERT, alternative-
splicing of hTERT transcripts (Ulaner et al, 2000) and post-tran-
scriptional phosphorylation of hTERT have been advocated (Kang
et al, 1999). Kiaris and Schally (1999) reported that telomerase
activity decreased in U87MG cells after treatment with an antago-
nist of growth hormone-releasing hormone MZ-5-156. The
authors found that the expression of hTERT was signiﬁcantly
decreased by MZ-5-156, whereas the levels of mRNA for hTR
and hTEP1 were unaffected. Moreover, the repression of the telo-
merase activity was not accompanied by a signiﬁcant decrease of
mRNA level for the c-myc protooncogene that regulates telomer-
ase (Kiaris and Schally, 1999). Our results are in agreement with
Kiaris’s, indicating that c-myc may not be involved in the regula-
tion of telomerase activity in U87MG cells. EGFR may regulate
the telomerase activity through other downstream molecules, but
not through c-myc. The signal transduction pathway of EGFR is
complex. EGFR can also activate protein kinase C (PKC), which
is a family of ubiquitous serine/threonine protein kinases involved
in growth control and tumorigenesis. Li et al (1998) reported that
phosphorylation of hTERT and hTEP1 by protein kinase C alpha
was an essential step in the activation of telomerase complex. In
U87MG cells, it is possible that EGFR up-regulates telomerase
activity through phosphorylation of hTERT and hTEP1 by protein
kinase C alpha, but not through transcriptional increase of hTERT
and hTEP1. The mechanism of EGFR regulating telomerase activ-
ity remains unclear.
In conclusion, this study provides evidence that EGFR plays an
important role in the regulation of telomerase activity of glioma
cells. Our ﬁndings provide new insights into both the biological
functions of EGFR and the regulation of telomerase activity. The
inhibition of telomerase activity triggered by antisense-EGFR treat-
ment may reﬂect yet another mechanism of antisense-EGFR
approach in tumour suppression.
ACKNOWLEDGEMENTS
This study was supported by CMB grant (XX Tian) from Health
Science Center, Peking University, and UGC grant (HK Ng) from
The Chinese University of Hong Kong.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Table 1 Tumour formation in nude mice (3 weeks)
No. of mice with tumours/ Tumour volume
Cell lines No. of mice injected (mm
3)+s.d.
U87 MG 4/4 1208+454
U87MG/pBabe 4/4 1696+553
AS-1 0/6
AS-3 6/6 323+208
Tumour volumes were determined by tridimensional caliper measurements and are
presented as the mean tumour volume (mm
3)+standard deviation (s.d.) of tumours
from four or six mice in two independent experiments.
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